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Abstract 
 
Parkinson’s disease (PD) is characterized by a progressive loss of dopaminergic neurons and 
represents a growing health burden to western societies. Like many neurodegenerative disorders 
the cause is unknown, however, as the pathogenesis becomes ever more elucidated, it is 
becoming clear that effective delivery is a key issue for new therapeutics. The versatility of today’s 
polymerization techniques allows the synthesis of a wide range of polymer materials which hold 
great potential to aid in the delivery of small molecules, proteins, genetic material or cells.  In this 
review, we capture the recent advances in polymer based therapeutics of the central nervous 
system (CNS). We place the advances in historical context and, furthermore, provide future 
prospects in line with newly discovered advancements in the understanding of PD and other 
neurodegenerative disorders. This review provides researchers in the field of polymer chemistry 
and materials science an up-to-date understanding of the requirements placed upon materials 
designed for use in the CNS aiding the focus of polymer therapeutic design. 
 
 
1. Introduction 
Parkinson’s Disease (PD) is a movement disorder that was described in 1817 by James Parkinson 
in his famous text “An Essay on the Shaking Palsy”. PD is a progressive neurodegenerative 
disorder which can give rise to a range of symptoms including the well-known triad of bradykinesia, 
rigidity and tremor. Parkinson’s disease (PD) and many neurodegenerative disorders (such as 
Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD) and 
multiple sclerosis (MS)), exhibit complex pathological features. Whilst these pathologies are being 
ever further elucidated, the causes (with the exception of genetic predispositions such as 
huntingtin gene mutations for HD) are more ambiguous. Many neurodegenerative disorders 
(including PD) are age related disorders and represent a growing healthcare burden to ageing 
populations, and as of yet, lack disease modifying intervention. Medications such as the gold 
standard levodopa for PD, result in a marked improvement in patient quality of life, but for a limited 
period [1]. They treat the symptoms of the disease not the underlying progression of the disease 
which, in the case of PD, is the dying back of the dopaminergic neurons in the midbrain. Disease 
modifying interventions are being sought based on gene therapies, new drug formulations, stem 
cells and other techniques, for which polymers of a variety of chemistries and structures are being 
considered for increasingly important roles. 
PD patients can exhibit a variety of phenotypic features, which can differ in severity from patient 
to patient depending of the underlying pathology, and can be accompanied by dementia and/or 
depression. Its cause can be divided into sporadic PD or familial PD where a genetic risk factor is 
known, and the age of onset can vary. In short, the pathology is complex and not consistent 
between patients, a matter that must be born in mind when discussing the merits of different 
medications, or during the design of future therapies. However, several inherent features of PD 
could be considered to offer relatively more straightforward opportunities for intervention than 
some other neurological disorders, which for the purpose of this review, makes PD an attractive 
example to address. The first of these features is the generally slow progressive nature of the 
disease. Unlike diseases such as ALS, which typically displays a rapid progression with 50% or 
patients dying within 2.5 years [2], PD usually progresses at a much slower rate [3] giving a longer 
period for potential intervention. The second feature, which sets PD (and other progressive 
diseases) apart from acute conditions such as traumatic brain injury (TBI), stroke, or spinal cord 
injury (SCI), is that at the time of diagnosis there is a modest window of opportunity within which, 
if the disease progression could be halted, a reasonable quality of life could be maintained. Clinical 
symptoms present after an approximate 50% loss of nigral neurons and an approximate striatal 
dopamine loss of 80% [4], providing a rationale for developing neuroprotective therapies to 
preserve these remaining neurons. Another key feature of PD for therapeutic intervention is the 
relatively select area of the brain that is affected. Whilst AD affects the hippocampus and cortex, 
and MS can affect any region of the CNS, PD predominantly affects the nigrostriatal pathway: the 
substantia nigra (where the cell bodies reside) and the striatum (where the neurons project). In 
summary, a therapeutic intervention aimed at treating Parkinson’s disease optimally could have 
an effect lasting years, and be targeted to the nigrostriatal pathway, either through direct 
stereotactic injection, or translocation across the blood brain barrier (BBB). This is clearly a 
formidable task, and whilst progress is being sought via clinical trials in gene therapies, direct 
protein infusions and cell therapies, there is an emerging field of polymer therapeutic research, for 
neurodegenerative diseases as a whole [5]. Growth factors such as glial cell line derived 
neurotrophic factor (GDNF), Neurturin (NTRN), brain derived neurotrophic factor (BDNF) and 
nerve growth factor (NGF) all show promise as a means of achieving neuronal protection or re-
innervation [6-10], and polymer therapeutics are likely to play a significant role in overcoming the 
problem of effective delivery [11, 12]. Although the field is in its infancy in terms of clinical 
translation, polymer science research is being developed in many areas (as outlined below) which 
may ultimately impact upon future PD therapies.  
2. Areas for Polymer Therapeutic Intervention 
There are several PD research areas which may result in future interventions involving 
therapeutics based either in part (the majority), or entirely (the minority), on polymer formulations. 
Figure 1 highlights potential areas for polymeric therapeutics in PD, where it can be observed that 
the majority of applications involve assisting delivery; either drugs, nucleic acids, cells, or proteins. 
For assisting the systemic delivery of pharmaceuticals to the brain, polymers may be used to alter 
solubility or circulation time, form micelles for drug encapsulation, or be used as linkers for 
targeting moieties. Alternatively, cationic polymers may be used to deliver negatively charged 
nucleic acids by condensing the nucleic acid, protecting it from degradation and assisting 
intracellular delivery. Due to the short half-lives of therapeutic proteins such as neuron protecting 
growth factors GDNF or NGF etc., sustained delivery platforms are being sought that protect the 
protein, releasing it slowly for a more prolonged effect. More recently, efforts have turned to 
developing platforms to assist cell therapies, such as injectable adherent microparticles or 
protective hydrogels.  
---FIGURE 1--- 
3. Polymer Design Considerations 
Polymers intended for therapeutic use in the brain or spinal cord must be synthesized holding 
several key design considerations in mind. Some of the most important considerations are outlined 
individually below.  However, it must also be noted that often parameters may well be closely 
linked, such as the polymer degradation profile and the polymer toxicity, where one affects the 
other, so cannot be treated as independent entities.  
3.1 Toxicity and Host Response 
Perhaps the first and most important aspect of polymer therapeutic design is the consideration of 
how the polymeric biomaterial will affect the host tissue/organism. Depending on the application, 
the expected toxicity can vary greatly [13]. For example cationic polymers for gene delivery often 
suffer an efficiency/toxicity tradeoff [14], whereas scaffolds for regeneration or cell delivery can be 
expected to exhibit little or no elevation in host response above that of a sterile media control 
injection [15]. The direct cellular toxicity of polymeric gene vectors is well documented in vitro. 
Indeed, the vast majority of research into new gene vectors comes accompanied by a report on 
cytotoxic affects. However, the situation in the brain or spinal cord is not only more complex than 
a 2D cell culture system, but also far less studied. Whilst in vitro toxicity analysis can give an 
indication of the direct toxicity in the brain, there are other host response effects which do not 
correlate so well, such as microglial activation and astrocyte reactivity. For example one study 
showed that direct toxicity to the striatum, caused by polymeric gene vectors, was inversely 
proportional to the density of microglia or astrocyte density surrounding the injection site [16].  
It is not clear whether the initiation of a microglial response by an injected biomaterial is necessarily 
detrimental to the surrounding tissue or not.  For example, microglial activity has been correlated 
with angiogenic microvessel formation after stroke injury in Sprague-Dawley rats [17]. For 
biomaterial implants containing a large number of transplanted cells, this microglial activity 
surrounding a graft may or may not be beneficial depending on whether the microglia are assisting 
microvessel formation thus promoting a new blood supply to the graft, or clearing foreign material. 
However, the glial scar formed around an injury to the CNS by reactive astrocytes [18, 19], 
including an injury left by a needle tract [16, 20, 21], is broadly considered to hinder axon growth 
and thus would hinder the ability of the graft to integrate with the host tissue during neuron 
replacement therapies for PD. Thus a polymer designed to reduce the reactivity of astrocytes may 
be beneficial, but it is not clear how this could inherently be achieved. However, polymer based 
hydrogels have extensively been shown to be capable of protein loading [22-25], thus hydrogels 
designed to assist cell based therapies to the brain could be loaded with the enzyme 
chondroitinase ABC, to allow a more permissive integration of the graft with the host. 
Chondroitinase ABC is an enzyme that digests chondroitin sulfate proteoglycans, the inhibitory 
component of the glial scar, and whilst much of the focus of its use has been towards SCI therapies 
[26, 27], use in the brain for assisting transplants should not be overlooked.  
Whilst there is ambiguity surrounding the exact effect of the microglial response to direct brain 
injection [28], the beneficial effect of immunosuppression towards the graft is also variable. For 
example, studies show immunosuppression to increase xenograft (human to rat) survival 
qualitatively [29] and quantitatively [30], but allograft transplantation into the striatum was not 
affected between immune-deficient/immuno-competent mice [31] other than to favor neuron 
differentiation [32]. The brain is now no longer considered a completely immuno-privileged region 
there is a degree of immune privilege, and the immune response is a major consideration for cell 
therapy [33]. Therefore materials designed to suppress negative effects of the host response could 
possibly play an important role in graft survival. To this end a hydrogel has been developed that 
releases an anti-inflammatory cytokine, interleukin 10, which is triggered by matrix-
metalloproteinase 9 secreted by activated microglia [34]. Consideration of immunogenic 
properties of hydrogels for graft protection is of course also critical. There is little point delivering 
beneficial therapeutics if the material itself invokes a larger immune response than that of the graft 
alone. To this end synthetic materials and lab synthesized peptide materials offer a means of 
lowering host immune responses to implanted materials.  
For any biomaterial intended for use in the brain certain design features can be inherently included 
to reduce the toxicity, including: reduction of surface charge, surface modification with inert 
polymers such as polyethylene glycol (PEG) (which can also reduce charge densities), use 
biodegradable polymers built from well tolerated monomers as a base material (such as the 
copolymer poly(lactic-co-glycolic) acid (PLGA)), use of degradable crosslinkers to assist material 
breakdown or, use synthetic/natural polymer hybrids to try to mimic the surrounding tissue more 
closely.  
Polymers designed for systemic administration have more complications which must be 
considered. The first and most obvious is the hemocompatibility or how the material interacts with 
blood. New polymers, designed for systemic applications, can be subjected to a simple battery of 
hemocompatibility tests in vitro, using human blood to assess parameters such as platelet 
activation, plasma clotting time and hemolysis [35]. Dendrimers, the highly-ordered, three 
dimensional branched polymers, which can be built up, one generation at a time, have been 
extensively researched for therapeutic delivery, including to the brain. However, studies have 
shown that generation 7 cationic poly(amidoamine)(PAMAM) dendrimers aggressively initiate 
blood clot formation which is likely caused through electrostatic interaction between the dendrimer 
amine group and the negatively charged fibrinogen [36]. A study from a different research group 
suggests that surface coating PAMAM with PEG may offer a significant safety improvement for 
systemic application. PEGylation reduced red blood cell hemolysis in vitro, which was most 
effective when PEG chains over 5KDa were grafted to the PAMAM core [37], suggesting that such 
strategies could be useful if the PEG layer does not interfere with the intended use of the 
dendrimer.   
---FIGURE 2 --- 
The second large toxicity/host response issue associated with systemic delivery applies to all 
vector systems and is independent of the polymer vehicle itself. This is the problematic effect of 
off-target delivery. Not only is brain targeted systemic delivery a task difficult unto itself, with a 
large proportion of off-target delivery to the liver, spleen or kidney [38], but the exact site of delivery 
within the brain is likely to be crucial for future protein/growth factor therapies. Early clinical efforts, 
administering the growth factor NGF to the brain via direct injection into the lateral ventricles, 
resulted in painful side effects that outweighed the therapeutic benefits [39]. The ventricle spans 
a large region of the brain (see figure 2), meaning that proteins delivered intraventricularly can 
exert their effect over a large area of the brain, with off-target effects. These effects were identified 
as Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites in the subpial 
region of the medulla oblongata, giving rise to symptoms of pain [40]. While the lateral ventricles 
lie in close proximity to the striatum where the dopaminergic neurons lost in PD terminate (see 
figure 2), their proximity to large brain regions such as the cortex render them an unlikely route for 
polymer therapeutic delivery for PD therapies. Indeed, a more recent trial involving NGF delivered 
directly to the basal forebrain in AD patients, via polymer encapsulated NGF secreting cells [41, 
42], did not result in any of these painful side effects experienced after intraventricular delivery, 
highlighting the importance of reducing off-target delivery.   
3.2 Degradability 
Another key design consideration for polymer therapeutics, is whether degradability should be 
incorporated into the polymer structure, and if so, by what means should it degrade, and which 
regions of the polymer should be cleavable (i.e. backbone or side-chains). Although at first it might 
seem likely that the majority of biomaterials for use in the brain or CNS should be biodegradable, 
this may not be the case, and would instead be application dependent. For instance, incorporating 
biodegradability into the polymer structure of nanoparticles designed for the delivery of genes or 
drugs to the striatum or substantia nigra, would eliminate accumulation issues, could assist in the 
release of cargo, and probably reduce toxicity (if the break-down products are non-toxic 
themselves). However, the NGF cell secreting implants mentioned earlier, composed of the non-
biodegradable materials polyethersulphone and polyeurethane, were well tolerated [41, 43], and 
in general inert metal probes such as for deep brain stimulation (DBS) are well tolerated although 
accompanied by a persistent glial scar [44, 45]. One study looked specifically at the host response 
to degradable (fast or slow) or non-degradable hydrogels, implanted into the striatum/substantia 
nigra of Sprague-Dawley rats [46]. The number of astrocytes within the vicinity of the implant was 
significantly lower for the slow or non-degrading hydrogels than the fast degrading hydrogel, 
suggesting that the continually changing environment created by hydrogel degradation causes 
more astrocyte activation. Thus, the decision of introducing biodegradability into the polymer 
structure is not clear-cut and will depend on the application. Non-degradable cell delivery devices 
essentially composed of poly-l-lysine coated glass beads appear to be well tolerated in the 
striatum (in terms of microglial activation)[47], whereas non-degradable PAMAM or 
polyethyleneimine (PEI) gene vectors cause tissue loss accompanied by a strong 
astrocyte/microglial response [16]. 
3.2.1 Hydrolysable Polymers 
Polymers containing esters, amides, acetals, carbonates, anhydrides, urethanes and phosphates 
are susceptible to cleavage in the presence of water, and the relative merits of each have been 
discussed elsewhere in the context of biomedical applications [48]. Incorporating such groups into 
the polymer backbone can thus facilitate biodegradation in vivo, however, rates depend on many 
factors, such as the number of groups (if copolymers with other non-degradable monomers), 
molecular weight of the polymer and monomer composition. For example, microspheres prepared 
from high molecular weight poly(D,L –lactic acid)(PLA) showed little degradation compared to the 
those composed of low molecular weight PLA which degraded much faster [49]. PLA is well known 
to degrade slower than poly(glycolic acid)(PLG), so the degradation profile can be tuned by 
varying the blend of the two monomers. This FDA approved copolymer, PLGA, has become one 
of the most researched polymers for biomedical applications for its tunable degradation rate and 
highly biocompatible nature (natural breakdown products) [48, 50].Much work has focused on the 
delivery of drugs or growth factors to the brain via targeted PLGA products which is discussed in 
more detail in later sections.  
3.2.2. Enzymatically Cleavable Polymers 
Naturally occurring polymers such as the proteins collagen, fibrin and elastin, or natural 
polysaccharides such as hyaluronic acid, heparin and chitosan, have been used as base materials 
for degradable biomaterial preparation [51, 52]. Semi-synthetic biomaterial scaffolds can be 
produced by combining these natural biopolymers with synthetic polymers such as PEG, with the 
aim of representing or mimicking host tissue more closely [53, 54], allowing cellular attachment 
[24], introducing enzyme cleavability [55], or improving the binding of growth factors [56]. These 
semi-synthetic materials are often designed in such a way that a functionalized PEG molecule 
(often branched) is used to crosslink the biopolymer either via an intrinsically present amine [57], 
via EDC/NHS activated carboxyl groups [58], or via a previously added functional group [59].  
A variety of hydrogels or scaffolds have been proposed for tissue regeneration in the CNS for 
neurodegenerative diseases therapies [60]. Many are used without transplanted cells and are 
designed to act as a supportive network (predominantly for applications in SCI, TBI or stroke). 
However, for applications in PD, many are used in conjunction with replacement cells, stem cells, 
or cytokine producing cells. However, regardless of strategy, allowing the host tissue to remodel 
the injected/implanted biomaterial by proteolytic activity of proteases such as matrix 
metalloproteinases (MMPs) would be advantageous. MMPs produced by neurons or supporting 
cells such as microglia, can allow invasion of dorsal route ganglion cells into PEGylated fibrinogen 
hydrogels in an in vitro model system, but the authors show that invasion does not occur in the 
presence of MMP inhibitors (see figure 3 adapted from [61]).  
---FIGURE 3--- 
Much recent work has focused on the design of peptide sequences that are susceptible to MMP 
cleavage, which can be incorporated into hydrogel or biomaterial design [62]. A group with much 
experience in starPEG-heparin biomaterials has recently shown a versatile approach to 
incorporate two peptides (one MMP cleavable, and one laminin-derived adhesion peptide) into a 
hydrogel structure [59]. Prior functionalization of maleimide terminated starPEG firstly with a cell 
adhesion peptide (Seq: SIKVAVGWCG), then a MMP cleavable domain with a protected second 
cysteine group (Seq: GCGGPQGIWGQGGCG) allows a peptide functionalized molecule that can 
crosslink maleimide functionalized heparin in situ via Michael addition (cysteine to maleimide) (see 
figure 4) [59].  
---FIGURE 4--- 
In this case dorsal root ganglion penetration of the gel was dependent on the presence of the cell 
adhesion peptide, and similar starPEG-heparin hydrogels have shown good biocompatibility in the 
rodent brain [24].  Semi-synthetic materials therefore offer a practical route to degradable 
materials provided that their design always takes into account correct natural polymer sourcing, 
reproducibility of production, sterilization, and ease of use during the surgical procedures.  
3.2.3. Intracellular Degradation (acid/reducing cleavage) 
Whilst large microspheres or macro scale structures such as hydrogels, scaffolds or nerve 
guidance conduits may rely on hydrolysis or enzymatic action for biodegradation, small (low micro, 
or nanoscale) delivery vectors may use intracellular cues for biodegradation. There is a growing 
research field aimed at developing polymer vectors to deliver drugs, genes or proteins to the 
central nervous system. Polymers therapeutics designed for systemic use may not benefit from 
introducing hydrolysable degradation into the structure. Instead, these vectors are designed to 
target and translocate the blood brain barrier, the highly selective endothelial layer which forms 
the largest area for exchange between the main blood supply and brain tissue [63]. In such a case 
it is likely that degradation upon cell entry would be more beneficial, allowing the vector to remain 
intact during transport in the blood. The two main methods of intracellular degradation use a 
change in pH to mediate cleavage within the endosome, or the presence of reducing conditions 
such as intracellular glutathione to break up the vector and potentially release the cargo [64].  
---FIGURE 5--- 
There are many acid cleavable groups which may be incorporated into polymer vectors, such as 
acetal or ketal linkages, orthoesters or the amine containing oxime or hydrazone groups, reviewed 
in detail elsewhere [64]. Figure 5 shows a library of acetyl containing acid cleavable polymers 
created by Fréchet and coworkers [65].  These forms of acid cleavable linkage, are also easy to 
incorporate into living polymerizations [66, 67], the preparation method of choice for many gene 
vectors [68, 69].  However, to date, the vast majority of degradable polymers for delivery to the 
brain use a reduction sensitive moiety (disulfide bond) instead.  
The presence of disulfide bonds in the structure of polymeric gene vectors allows a reversal of the 
well-reported correlation between increasing toxicity with increased transfection performance [14]. 
Non-degradable polymer vectors often showed higher transfection capabilities with increasing 
molecular weight, but this trend would typically be accompanied by increasing toxicity [70, 71]. 
However, by linking small (2kDa) PEI chains via disulfide bonds, Goepferich and coworkers were 
able to make a vector large enough for efficient gene transfer but degradable in a sufficient time 
scale to reduce toxicity [14]. More recently, Kim and coworkers produced branched PEIs based 
on the linkage of thiol terminated 1.2kDa branched PEIs macro monomers (see figure 6) for 
marker gene (red fluorescent protein) delivery to the rodent brain [72]. In vitro toxicity analysis of 
these vectors delivering microRNA (mRNA) to Neuro2a cells showed that polyplexes (polymer 
complexed with nucleic acids via electrostatic attraction) formed at the optimum polymer/mRNA 
ratio of 13.3/1 the degradable vector allowed ~ 70% cell viability compared to ~25% cell viability 
for the non-degradable PEI control [73]. 
---FIGURE 6--- 
Poly(β-amino esters)(PAEs) are much studied for non-viral gene delivery applications as the ester 
group gives rise to their inherently degradable properties [74-76]. However, a large study 
comparing a variety of PAEs showed that the addition of disulfide bonds via cysteine produced 
higher transfection results of small interfering RNA (siRNA)(presumably through quick siRNA 
release) but interestingly resulted in a decline in DNA transfection compared to non-reducible 
controls [77]. Another intriguing study shows that a disulfide bond incorporated into a cyclized 
polymer structure, that consists of single chains attached to themselves via intramolecular 
cyclizations, allows a high transfection capability and low toxicity even though reduction of the 
bond does not result in cleavage of the polymer, but instead an “untying” of the polymer chains 
[78].  
---FIGURE 7--- 
Whilst some studies have shown a reduced performance of reducible gene vectors [79], others 
have reported an increase in efficiency [14, 80]. Using the reducing conditions within the cell to 
break down polymeric delivery devices clearly has much potential to improve delivery efficiency 
and lower toxicity, two factors presently presenting a barrier to the true realization of non-viral 
gene delivery to the brain.  
3.3. Adding Functionality (Targeting, Cell Entry etc.) 
Currently, the vast majority of drugs administered for diseases such as PD, are administered 
orally, requiring them to enter the blood stream and finally cross the blood brain barrier (BBB) to 
mediate their effect in the brain. This non-invasive approach has high patient acceptance but 
severely limits the type of drug that can be administered, with proteins and charged molecules 
being prevented entry to the brain [81]. Routes to bypass the BBB, such as stereotactic surgery, 
are a possible option for one-off interventions (such as cell replacement therapies), but remain a 
difficult task for continuous infusion [82-85]. Other routes to CNS administration involve BBB 
disruption and/or nasal administration [86, 87]. Whilst these areas of research are gaining 
momentum (reviewed elsewhere [81]), polymer therapeutics are still likely to require specific 
functionality in their design. Another hurdle hindering the progress of therapeutic delivery to the 
CNS is the ability to design polymer vectors capable of crossing the blood brain barrier, targeting 
specific cell types and avoiding off target delivery to organs such as the liver and spleen. Even 
vectors delivered by stereotactic injection, which is the main injection method analyzed to date for 
non-viral gene delivery to the brain [88], may still require the addition of specific cell targeting 
moieties [89, 90], for cell surface receptors [91], cell penetrating peptides or nuclear localization 
sequences [80] to deliver with high efficiency. There is clearly an argument for polymer vectors 
with a simple design and much of the polymer vector research by Wang et al., has focused on 
very simple “one pot” synthesis strategies, such as deactivation enhanced ATRP [66, 92] or RAFT 
polymerization [67], to allow easy scale up and increased reproducibility. However, nature’s highly 
effective adenoviral vectors are not such a simple design, and consist of a highly organized 
structure containing multiple proteins [93-95]. There is therefore perhaps a tradeoff between 
simplicity/translation to the clinic/viable upscale (supply), and complexity/efficiency/demand. The 
aim of much of Wang’s research is therefore to make simple and efficient vectors as a starting 
point which contain free vinyl groups [71, 96, 97] to allow simple post synthesis functionalization 
via Michael addition for example with antibody fragments [98]. However, more complex delivery 
systems may include multiple functional moieties such as a polymalic acid vector developed for 
systemic delivery of antisense oligonucleotides against glioblastoma (see figure 8)[99]. The vector 
includes two targeting antibodies, pH triggered endosomal escape moiety, carboxylate groups to 
improve solubility, and a tracking Alexa Fluor. 
---FIGURE  8--- 
Adding targeting moieties into the structure of polymeric gene or drug carriers for improving 
systemic delivery to the brain has been extensively investigated (reviewed elsewhere) [100, 101], 
but has also been proposed for assisting access to the CNS via intra-nasal administration [102-
105]. The discovery of transferrin receptors specifically on the endothelium of capillaries of the 
brain [106] has led to much research using either the monoclonal antibody against transferrin or 
conjugating the transferrin glycoprotein itself to the polymer vector [107-112]. However, due to 
high endogenous levels of transferrin nearly saturating the receptors, antibodies against the 
transferrin receptor, that do not compete with transferrin binding, such as OX26 (rat) and RI7217 
(mouse) offer practical alternatives for in vivo studies [113, 114]. Research has also turned 
towards the use of antibody fragments to functionalize polymers [98], due to the improved tissue 
penetration, reduced immunogenicity, or increased packing density of these small fragments 
compared to the parent molecule [115]. Immunoliposomes targeted with the OX26 antibody 
showed greater gene delivery than non-targeted liposomes [113], whilst in a comparative study 
RI7217 targeted liposomes showed better brain uptake than four other targeting moieties [114].  
Many targeting ligands have been used to improve the efficiency of gene protein or drug delivery 
to the brain such as rabies viral glycoprotein (RVG) [116-118], lactoferrin [38, 119, 120], peptide 
TGN [121-123], or  Tet1 [90] to name a few (more reviewed elsewhere [88]). The improvements 
that ligands such as these provide, although sometimes modest, give a strong rationale for the 
inclusion of specific groups into the polymer design, to aid cell/tissue targeting, cell uptake or 
nuclear localization etc. It is also noteworthy that cell penetrating peptides such as Arg-9, 
penetratin, and TAT, themselves maybe neuroprotective, thus offering an addition advantage for 
functionalized vectors, but obscuring from where benefits arise [124]. Whilst very efficient delivery 
to brain has recently been achieved using anti-glioblastoma RGD modified polymer micelles [125], 
PD therapeutics may also require specific targeting of the striatum, or the dopaminergic neurons 
themselves, to overcome the off-target effects mentioned previously [39, 40]. As a study with 
targeted GDNF fusion proteins has shown, reducing off target growth factor effects are difficult 
[126], and perhaps specific astrocyte or neuron targeting would be more feasible for gene therapy. 
The use of a region specific promoter, such as GFAP or tyrosine hydroxylase, could restrict 
expression to astrocytes [127] or to catecholaminergic neurons in the brain respectively [128, 129].   
3.4. Structure 
Designing a polymer therapeutic requires consideration of the toxicity, degradability, and 
functionality, which in turn will affect the choice of monomer composition. However, another 
important design consideration is the polymer structure, which will not only affect the choice of 
monomers used, but also how they are to be arranged in the polymeric structure. Depending on 
whether a macroscale hydrogel is being designed or a nanoscale drug delivery device, the 
polymer structure may be vastly different. The desired structure will not only determine whether 
crosslinking monomers (such as divinyls) are used, but also how drugs are loaded [130], nucleic 
acid interactions [96, 131, 132], and mechanical properties [133] to name but a few.   
Progress in polymer synthesis techniques has allowed the formation of a variety of polymer 
structures. Whilst conventional free radical polymerization can easily be used to form linear 
polymers, particularly from monomers containing a single vinyl group, control over the molecular 
weight and the distribution of molecular weight can be poor. The initiation process is slow and 
continuous, and the termination process is uncontrolled, leading to chain growth starting or 
stopping at different times, hence the formation of a variety of chain lengths, (or high polydispersity 
index) [134]. Controlled radical or "living" radical polymerization however, creates a dynamic 
equilibrium between the active species capable of propagation, and the deactive species (not 
permanently terminated) halting the chain growth until next activated (see figure 9) [135].  
---FIGURE 9--- 
In this way the reaction procedure can be controlled so that the desired molecular weight can be 
achieved with a narrower polydispersity. A variety of polymer architectures can be formed 
depending on the polymerization technique used (e.g. nitrox-oxide polymerization, atom transfer 
radical polymerization or reversible addition fragment polymerization), the monomers used (e.g. 
mono functional, multi-functional), and/or strategy employed (e.g. starting with a multifunctional 
core for star polymer synthesis) [69].  
---FIGURE 10--- 
Figure 10 shows the major polymer architectures that could be used for designing polymer 
therapeutics for the CNS. A brief overview is given below, because many of these structures will 
appear in the last section of this review, where polymer therapeutics specifically used for PD 
applications are discussed. A simple example, where the specific structure of a polymer bears 
critical importance to its function, can be seen when a dendrimer can alter whether it does or does 
not inhibit the aggregation of the Parkinson's disease protein alpha-synuclein [136]. The function 
of the outlined polymer structures is not limited to nanoscale delivery devices; they can be 
designed as crosslinkers for materials such as microparticles/macroscopic hydrogels, tethering 
agents for functional moieties, or simply side chains to adjust hydrophilicity.   
3.4.1. Linear Polymers  
---FIGURE 11--- 
These can typically be formed via simple ring opening polymerization reactions, to form polyesters 
such as poly(lactic acid), poly(glycolide), poly(caprolactone) and the copolymer PLGA [137]. 
Controlled radical polymerization can also be used as another simple example, whereby linear 
chains are formed by the polymerization of monomers containing a single vinyl group, such as 3-
aminopropyl methacrylamide (APMA), 2-dimethylaminoethyl methacrylate (DMAEMA) or N-(2-
hydroxypropyl)methacrylamide (HPMA) (see figure 11) [68, 69]. Being simple to produce with 
good size control, linear polymers are much studied e.g. linear PEG chains for altering drug 
solubility/circulation times, or linear PEI for transfection agents. However, the functionality of linear 
polymers is limited to the monomers used, and the two end groups. In contrast, branched polymers 
contain a greater number of chain ends per single molecule, allowing greater possibility for post 
functionalization. Another way to introduce functionalization for applications such as gene delivery, 
is via living copolymerization, either forming diblock copolymers which can self-assemble into 
micelles etc., or forming statistical or graft copolymers containing different groups or chains 
attached to a linear backbone [138].   
3.4.2. Branched Polymers 
As figure 10 shows, branched polymers can be formed as a variety of structures, such as branched 
or hyperbranched polymers, highly ordered three dimensional dendrimers or chains organized in 
a star shape via a central core unit, to name some common types. The occurrence of branching 
gives rise to the possibility of greater functionalization due to the greater number of chain ends. 
Cationic polymers for applications in gene delivery, such as PEI, are commercially available as a 
linear structure (typically 22kDa) or branched structure (typically 25kDa) where the linear 22kDa 
PEI typically shows a higher transfection capability [139, 140]. However, in contrast, studies of the 
tertiary amine containing DMAEMA polymer show that branched polymers, either hyperbranched 
or in a star shape, show a higher transfection capability than a linear DMAEMA control polymer 
[97, 141]. Dendrimers, branched polymers with a highly ordered structure [142], have been 
extensively researched for a wide range of biomedical applications [143], some of which could be 
tailored to PD therapeutics, such as gene/protein/drug delivery or to prevent harmful protein 
aggregation (see section 4).  
---FIGURE 12--- 
Several groups using controlled living polymerizations as a route to branched structures report the 
presence or likelihood of both intermolecular cross-links (between different polymer chains) and 
intramolecular (internal cyclizations) within the same polymer chain [144-146]. Furthermore, Gao 
and Matyjaszewski used atom transfer radical polymerization (ATRP) [147, 148] to 
homopolymerize a divinyl monomer under dilute conditions to synthesize nanogel cores as a new 
route to star polymer architectures (see figure 12) [149]. Recently Wang and co-workers have 
been able to shift the intermolecular/intramolecular balance to form either utmost hyperbranched 
polymers, or single chains self-linked by intramolecular crosslinks by in situ deactivation enhanced 
ATRP [150]. By controlling the monomer to initiator ratio, along with the percentage of the 
deactivating CuII species (enhances deactivation depicted in figure 9), single cyclized molecules 
can be formed which can be used for gene vectors for neural cells (figure 13) [78, 96] (add in new 
reference ).  
---FIGURE 13--- 
3.4.3. Cross-linked Networks 
Networks of cross-linked polymer chains can occur on a variety of scales, from macroscopic gels 
that retain water (hydrogels), to finite networks on the microscale or nanoscale (microgels or 
nanogels). The term “cross-linked network” may refer to either intermolecular or intramolecular 
crosslinks and may refer to either a covalent bond (chemically cross-linked) or physical 
interactions such as electrostatic interactions, hydrogen bonding, or hydrophobic interactions 
(physically cross-linked). Aside from core precursors for star polymers (see figure 12), nanogels 
may be designed for therapeutic delivery [151, 152]. Macroscopic hydrogels/scaffolds may be 
designed for neuron guidance applications, cell delivery systems or growth factor/drug depots for 
sustained release [153-156]. Network formation may be induced via a variety of methods. For 
applications in Parkinson’s disease, where the material must be injectable, crosslinking can only 
occur prior to injection if nano/microscopic networks are formed [157], or if the hydrogel has shear 
thinning properties [158, 159], allowing release through the injection cannula. Therefore, much 
attention has been given to in situ gelling materials, which form a hydrogel upon or soon after the 
injection procedure [160]. In this case, the precursor materials must not be toxic, ruling out the 
much used EDC/NHS chemistry, and must form a hydrogel at 37oC in a suitably short time frame, 
but not too quickly as to clog the injection cannula during the injection procedure (usually greater 
than two minutes). To this end, one obvious stimuli to trigger gelation is temperature. Temperature 
sensitive polymers, which are a liquid solution at room temperature, can form hydrogels when the 
lower critical solution temperature (LCST) is surpassed (typically below 37oC for biomedical 
applications), due to the change in the hydrophobicity [161, 162]. Pure PEG based polymers or 
other hydrophobic hydrogels suffer the drawback that they are unsuitable for cell delivery 
applications as cells attach poorly. Semi synthetic hydrogels offer an attractive means to providing 
a substrate for cell attachment, and can be designed to form a gel in situ by mixing of crosslinker, 
such as PEG, immediately prior to injection, to crosslink naturally occurring materials such as 
collagen [15] or heparin [24]. One final means to forming a cross-linked network, worth mentioning 
in the context of PD therapies, has been to use a branched PEG polymer containing reducible 
(disulphide) and non-reducible crosslinkers, activated to gel by the addition of glutathione [157]. 
The reducing agent glutathione and its precursor N-acetyl cysteine have been studied as a means 
to reducing reactive oxidative species in the brain [163]. Although efficient glutathione (or 
precursor) delivery remains an obstacle, greater superoxide activity and decreased levels of 
reduced glutathione are well documented in PD, indicating oxidative stress is a mechanism of cell 
loss [164-166]. The PEG based polymer relied on non-reducible ethylene glycol dimethacrylate 
(EGDMA) as branch points, and on glutathione sensitive links, to be reduced to thiols, which could 
then spontaneously crosslink with free vinyl groups remaining on the polymer chains to form a 
crosslinked network (see figure 14)[157]. Although this was very preliminary research, the concept 
could, in principle, be applied to PD cell transplantation therapies for a combined gel formation 
and glutathione delivery. However, cell attachment should again be considered, perhaps by 
adding cell adhesion ligands such as RGD into the hydrogel structure [59].   
---FIGURE 14--- 
4. Applications in Parkinson’s disease: Current Progress and Future Perspectives 
As figure 1 attempts to depict, there are several possible areas where polymer therapeutics may 
impact on PD. Nanoscale polymers may assist drug or gene delivery, or inhibit protein 
aggregation, whilst microscale materials may allow more effective protein delivery, such as growth 
factors. Macroscopic polymer hydrogels might be able to improve the transplantation process by 
providing a protective medium to which cells can attach. In addition, hydrogels may also be used 
to deliver growth factors with the aim of protecting neurons, providing neuron guidance cues or 
improving cell survival post transplantation. Current progress in the above mentioned fields are 
highlighted below. 
4.1. Polymers as Drug Carriers 
Dopamine, the neurotransmitter depleted in Parkinson’s disease, acts upon the dopaminergic 
pathways as shown in figure 2: mesolimbic/cortical pathway, tuberoinfundibular pathway and 
nigrostriatal pathway. In PD, the death of neurons in the latter pathway results in a deficit of 
dopamine, in particular in the putamen where only 1% of dopamine was found in patient autopsies 
compared to healthy controls [167]. The replacement of dopamine, via the precursor levodopa (or 
L-DOPA) (which can cross the BBB) forms the mainstay treatment for PD [168], however, it is 
associated with undesirable side-effects such as dyskinesias and a host of non-motor 
complications such as nausea, hallucinations etc., [168, 169]. The inevitable intermittent nature of 
oral delivery produces peaks and troughs of L-DOPA levels in the blood and brain, which appears 
to compound these side-effects [170-172] and better means of delivery are being sought [172]. 
Indeed, for many existing PD drugs, drug delivery systems are being developed either to sustain 
more constant pharmacological levels or improve therapeutic efficiency by better 
targeting/delivery across the BBB [173, 174]. Polymer therapeutics may therefore play a role in 
reducing side effects and improving efficiency of current drugs, or may allow the development of 
new drugs capable of crossing the BBB [175, 176].  
The biodegradabe linear polysaccharide, chitosan, contains a primary amine group per repeating 
unit, allowing interaction with hydrophilic drugs such as dopamine. Dopamine loaded chitosan 
nanoparticles could be formed with an average diameter of 110nm [177]. Dopamine is too 
hydrophilic to pass through the BBB as a free drug, however, intraperitoneal administration of 
dopamine loaded chitosan nanoparticles caused an increase in striatal dopamine output [178]. 
Chitosan has also been shown to transport nucleic acids such as siRNA to the brain (more on 
gene delivery to the brain in section 4.2) when functionalized with PEG and the TAT peptide [179], 
or deliver peptides to inhibit caspase activity [180, 181].  
PLGA is another biodegradable material (figure 15) that has been used for drug delivery to the 
brain for applications in PD.  
---FIGURE 15--- 
Microparticles of PLGA encapsulating a drug can be formed using emulsions, for example oil-in-
water/solvent evaporation [182], or water-in-oil-in-water emulsions [183]. In this way, particles 
containing the free drug can be purified, freeze-dried and stored for later use. As mentioned 
earlier, the intermittent administration of oral L-DOPA administration can be problematic so a more 
controlled release of the drug could potentially improve the side effects of L-dopa induced 
dyskinesias.  More recently a prodrug of L-DOPA has been produced for dopaminergic stimulation, 
termed L-dopa-α-lipoic acid.  It is less susceptible to enzymatic conversion (e.g. by catechol-O-
methyltransferase and monoamine oxidase), resulting in longer periods of activity compared to 
standard L-DOPA.  D'Aurizio et al., encapsulated L-dopa-α-lipoic acid within PLGA microparticles 
and showed that striatal dopamine levels could be increased post subcutaneous administration of 
such a delivery system (see figure 16) [184]. The remarkable feature of this work is the 
pharmacokinetic properties of the delivery, which gave rise to relatively steady striatal dopamine 
levels over a period of four days.  
---FIGURE 16--- 
Two further studies showed that the delivery of levodopa methyl ester in conjunction with 
benserazide (a peripheral dopa-decarboxylase inhibitor) via PLGA particles could reduce L-DOPA 
induced dyskinesias [183, 185]. A reduction in phosphorylation of the non-dopmainergic 
glutamatergic receptor α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) was 
observed [185], a receptor previously shown to be involved in L-DOPA induced dyskinesias [186].  
To model L-DOPA induced dyskinesias, firstly a commonly reported model of PD was established 
using the toxin 6-hydroxydopamine (6-OHDA) that (when given at the appropriate dose) 
selectively destroys dopaminergic neurons, and then L-DOPA is administered over a period of 
weeks in a manner that mimics the intermittent dosing that results from taking tablets at intervals 
during the day. The acute toxin models of PD, such as 6-OHDA, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and rotenone models, comprise the most common models but are not 
without criticisms [187] and more pathologically relevant models are being sought [188-192].  
However, the chronic toxin exposure models can indeed mimic the human PD nigrostriatal lesion 
[193] and so the toxin induced PD models are still used to validate the therapeutic efficiency of 
new therapies. 
---Table 1--- 
Aside from the dopamine precursor L-DOPA,  agonists that act upon the dopamine receptors are 
widely used, often as a first line treatment [169]. These are not without their side effects (many 
similar to L-DOPA treatment) and research groups are also investigating the use PLGA based 
microscale carriers as a means of sustained release of agonists such as apomorphine [194] or 
delivery of rotigotine [195, 196] to the brain. Wang et al., were able to show that rotigotine loaded 
PLGA microspheres administered in conjunction with L-DOPA, reduced the abnormal involuntary 
movements (dyskinesias) associated with L-DOPA therapy compared to the control group (L-
DOPA alone) in the 6-OHDA rat model of PD [195].  These preclinical studies, showing the ability 
of PLGA micro/nanoparticles to deliver therapeutic agents to the animal brain, could mean that a 
fundamental change in the way PD drugs are administered might not be too far from reality. 
Combining drugs that are already approved by regulatory bodies, and PLGA that already has FDA 
approval for a host of devices, could mean an easier route to acceptance for tackling the problem 
of “on-off” symptoms than more radical approaches such as viral delivery of enzymes involved in 
the dopamine synthesis pathway [197-200]. PLGA spheres could  also be used to deliver other 
therapeutic agents such as MAO-B inhibitors [201] and attempt to modify the disease process by 
delivering antioxidants [202], cytoprotective drugs such as urocortin [104, 203], or neuroprotective 
growth factors (covered in section 4.4).    
4.2. Polymeric Gene Vectors 
The number of non-viral transfection studies performed in the mammalian brain to date is well 
over 65 [88]. The majority of these studies are with liposome or polymer vectors, and many use 
marker genes to assess the effectiveness of the vector. For example, the early studies in the 
Demeneix group used liposomes and PEI to deliver the marker genes for β-galactosidase or 
luciferase to the newborn mouse brain [204, 205]. Since then much work has focused on the 
difficult task of transfecting the adult rodent brain with functional genes for a therapeutic outcome 
in an experimental model of disease. This section will highlight some of the recent progress made 
towards accomplishing this goal.   
Despite the early success of PEI vectors for the delivery of marker genes to the rodent brain[204], 
the more recent studies, delivering therapeutic nucleic acids to models of disease, have focused 
heavily on poly-L-lysine (PLL) based vectors. PEI has been shown to cause significant toxicity in 
the striatum, thus researchers have sought to reduce the toxicity through delivery via collagen 
spheres [16], encapsulation within liposomes [206], or using PEG to reduce the charge density 
[90]. PLL, the natural homopolymer of L-lysine, has been modified by the addition of neurotensin 
for gene delivery directly to dopaminergic neurons to act on their high affinity neurotensin 
receptors (the entire work is concisely reviewed elsewhere [207]). The delivery of the gene 
encoding human GDNF, via the neurotensin-PLL vector, to the rat substantia nigra one week after 
the 6-OHDA lesion, was able to induce re-innervation of the striatum where the dopaminergic 
neurons project (see figure 17) [208]. 
---FIGURE 17--- 
Another PLL based variant used L-cysteinyl-poly-L-lysine conjugated to 10kDa PEG to form a 
transfection vector that could compact DNA into polyplexes of 11nm diameter or less. This small 
size allows the transfection of post-mitotic cells and could mediate GDNF transgene expression 
in the rat striatum for up to three weeks post intrastriatal injection [209]. A follow up study showed 
that GDNF transgene expression could be observed for up to six months and showed that GDNF 
levels were higher in the 6-OHDA model than in the healthy brain [210]. Since the 6-OHDA causes 
a large upregulation of astrocytes in the rat 6-OHDA model [211] it is likely that this increased 
GDNF level is due to the transfection of astrocytes, being greater in number in the 6-OHDA model 
than the healthy brain [210]. A previous study has shown that primary astrocytes extracted from 
the midbrain of the newborn rat are far less amenable to non-viral transfection than immortalized 
Neu7 astrocytes [96]. However, a comprehensive study of a library of poly(β-amino esters) 
showed that one specific composition (1,4-butanediol diacrylate “backbone”, 4-amino-1butanol 
“side chain”, with the end-capping agent 1-(3-aminopropyl)-4-methylpiperazine) was able to 
transfect healthy astrocytes where others, including the lipofectamine2000 control, failed to do so 
[75]. The ability of polymer gene vectors to be efficient at transfecting astrocytes is probably an 
important design criteria [127], especially for secreted proteins such as GDNF, however it must 
be borne in mind that astrocyte numbers are not elevated in the human PD condition either in the 
substantia nigra or the putamen [212]. Another important factor which must be considered when 
designing gene delivery vectors for stereotactic injection into the brain is the charge of the 
polymer/nucleic acid complex. Whilst the aforementioned studies show complexes typically 
cationic in nature, a recent study showed that greater spread away from the injection site could 
be achieved by anionic complexes, as they have less affinity for cell surface proteoglycans than 
the cationic counterparts [213].  
The above studies, using a PLL based vector, observed the effect of transfection after direct 
stereotactic injection into the brain, and used the 6-OHDA as a toxin to selectively destroy the 
dopaminergic neurons. However, the same basic vector has been used mediate GFP transgene 
expression in several brain regions (including the striatum) after intranasal delivery [85]. In 
addition,  a PLL based vector has also been analyzed for its ability to mediate GDNF transgene 
activity in the rat brain after systemic injection [214]. To facilitate translocation across the BBB, 
this dendrigraft PLL was functionalized with PEG and angiopep, a ligand that specifically binds to 
the low-density lipoprotein receptor-related protein which is overexpressed on the BBB. This study 
used the pesticide rotenone to model PD, which, when administered systemically, can cause loss 
of the dopaminergic neurons and α-synucleinopathy, or just dopaminergic neuron loss without the 
α-synucleinopathy when administered via direct stereotactic injection [215]. The angiopep 
conjugated PLL vector was able to produce GDNF over-expression in the rat brain in a dose 
dependent manner, resulting in a greater number of tyrosine hydroxylase (TH) positive 
(dopaminergic) neurons surviving than a green fluorescent protein control group [214]. The same 
group functionalized dendrigraft PLL with the rabies virus glycoprotein peptide (RVG29) again via 
a difunctional PEG, to deliver anti-apoptotic interference RNA to the rat brain [118]. RVG29 is a 
29 amino acid peptide capable of binding the nicotinic acetylcholine receptor widely expressed 
throughout the brain and BBB [216]. Systemic delivery of this PLL loaded with short hairpin RNA 
to knockdown caspase-3 expression was found to significantly improve motor activity during 
behavioral tests in the rotenone PD model in comparison to saline control injections or the non-
functionalized vectors [118].  
Whilst the vast majority of non-viral gene delivery studies, which have focused on a functional 
(behavioral) outcome in a PD model, have used PLL as the cationic component for nucleic acid 
condensation, others have used the PAMAM dendrimer. Using a difunctional PEG spacer, a 
lactoferrin ligand was attached to generation 5 PAMAM [119, 217]. Lactoferrin binds to the 
lactoferrin receptors present in the brain endothelial capillary cells of the BBB [218, 219], and 
transport across the BBB is reported to be unidirectional [219], giving lactoferrin the potential to 
be a highly efficient means of targeting the brain. Delivery of the GDNF encoding gene resulted in 
a significant behavioral improvement in both the 6-OHDA PD model [119], and the rotenone model 
[217].  
There are two other non-viral vectors, which although do not fit into the classic polymer structures 
outlined in section 3.4, are worth mentioning due to their high efficacy at delivering nucleic acids 
across the blood brain barrier. The first, Trojan horse liposomes, are PEGylated liposomes with 
insulin or transferrin monoclonal antibodies attached (reviewed extensively elsewhere [220]). An 
early report showed gene expression in the brain following a single intravenous injection [109], 
and has since been used to deliver therapeutic genes such as GDNF to the brain in PD models 
[129]. The second, targeted exosomes, are vesicles produced by cells [221], which were 
functionalized with the rabies virus glycoprotein to deliver siRNA neurons to the mouse brain after 
systemic injection. The targeted exosomes could mediate successful knockdown of BACE1 – a 
specific Alzheimer’s disease protein, showing great potential for the future gene therapies in 
neurological disorders (reviewed elsewhere [222]).  
Despite much general research [223], polymer vectors based on the tertiary amine containing 
DMAEMA monomer have received less attention specifically for transfection of neurons or for 
neuronal applications. Studies have shown that the transfection of primary astrocytes is possible 
using DMAEMA vectors [96], and that they can mediate transgene expression in the spinal cord 
when released from collagen conduits in the completely transected rat spinal cord injury model 
[224]. However, a recent study has assessed the ability of peptide TGN functionalized DMAEMA 
vectors to mediate gene delivery to the mouse brain [122]. These vectors, formulated with PEG to 
form micelles, were able to mediate widespread transfection of the brain. Interestingly, non-
targeted vectors showed only slight transfection around the lateral ventricle, but the targeted 
vectors could mediate transfection in the striatum and the substantia nigra, which are both regions 
of interest for PD therapies.   
---Table 2--- 
Whilst much progress is clearly being made in the field of non-viral gene delivery, clinical trials 
involving viral delivery of genes such as NGF [225], glutamic acid decarboxylase [226],   neurturin 
[227] (a structural relative of GDNF), and ProSavin (tyrosine hydroxylase, AADC, and 
cyclohydrolase 1) [228] to the brain are providing mounting evidence for the safety of such 
therapeutic strategies. By 2012, 28 clinical trials involving gene therapies for neurodegenerative 
disorders had taken place [229]. Although greater efficacy is being sought, some studies lack 
significant improvement, which may be in part due to patient selection criteria, which could 
perhaps be improved by selecting patients in an early stage of the disease process. However, 
non-viral vectors are not without their advantages, which could materialize in later years once the 
efficacy has been improved. If viral mediated gene therapy can pave the way to prove the principle 
that gene therapies can be of benefit to PD patients [230, 231], then perhaps the advantages of 
non-viral vectors such as ease of handling/distribution/storage, and ability in most cases for large 
scale production could emerge allowing widespread therapeutic intervention. In addition, targeted 
vectors, with the ability to cross the BBB [232], would significantly reduce the cost of intervention. 
However, the transfection of off target organs such as the liver and kidney must also be overcome 
as figure 18 serves to highlight [73].  
---FIGURE 18--- 
4.3. Polymeric Inhibitors of Protein Aggregation 
The use of polymeric nanoparticles in an attempt to reduce the fibrillation or aggregation of disease 
causing proteins is an exciting and more recent area of research. Many of the neurodegenerative 
diseases have pathologies characterized by the presence of protein aggregates, such as 
intranuclear inclusions in HD and polyglutamine diseases (e.g. huntingtin and atrophin-1 
respectively), neuritic plaques and neurofibrillary tangles in AD (e.g. Aβ peptide and 
hyperphosphorylated tau), or aggregates of the prior protein in Prion’s disease, or the α-synuclein 
protein containing Lewy bodies in PD [233].  Nanomaterials, such as quantum dots, polystyrene 
spheres, cationic polymers and dendrimers have been used to either reduce the rate, or stop the 
process of protein aggregation or fibril formation. The fibrillation process starts initially with 
nucleation of monomeric peptides forming subcritical or critical nuclei of oligomers, followed by 
elongation to mature fibrils. Early work in this field working with amyloid β protein has shown that 
the lag phase, before fibril formation, can be increased by using copolymers of N-
isopropylacrylamide: N-tert-butylacrylamid, termed NiPAM:BAM [234]. The authors reasoned that 
this extension of the lag phase is due to the association of monomeric or oligomeric protein to the 
nanoparticle surface (as shown in figure 19) rather than to each other to elongate the fibril.  
---FIGURE 19--- 
The nature and mechanism of fibril formation is indeed complex with a balance between promoting 
and preventing fibrillation being shown even for materials of the same composition. For example 
the aforementioned NiPAM:BAM polymers were previously shown to promote fibril formation of 
human β2-microglobulin [235]. In addition, increasing the hydrophobicity of the copolymer resulted 
in a reduction of the lag time of amyloid β protein back to nearly that of the protein incubated in 
nanoparticle free solution [234].  Another study, which used amino modified polystyrene 
nanoparticles showed that low concentrations (0.02 or 0.05 mg/mL) caused quicker amyloid β 
protein fibril formation then the no treatment group [236]. However, in stark contrast, the high 
concentration (1.1 mg/mL) retarded fibril formation significantly as shown in figure 20.  
---FIGURE 20--- 
In terms of PD, studies have investigated the ability of cationic dendrimers to inhibit fibrillation of 
α-synuclein, the protein present in Lewy bodies (protein aggregates involved in PD pathology). α-
synuclein can exist in a variety of conformation states (e.g. partially folded, oligomeric, or fibrillar 
or amorphous aggregates) and much evidence links α-synuclein misfolding to both sporadic and 
familial PD [237].  
Reducing the fibrillation/aggregation of α-synuclein may therefore play a role in the affecting the 
progression of PD. PAMAM dendrimers (generations (G) 4, 5 and 6) used as purchased without 
modification were able to reduce α-synuclein fibrillation as measured by the Thioflavin T assay 
[238]. This occurred for all three generations, and the effect of concentration analyzed for G5 
PAMAM showed a concentration dependence on the degree of inhibition. A different study showed 
that whilst G4 PAMAM showed inhibitory effects on α-synuclein fibrillation, the middle generation 
G3.5 PAMAM did not [136]. The number of end groups remains the same, however whereas G4 
PAMAM has primary amine end groups, the G3.5 PAMAM has carboxyl groups. This would 
indicate that surface amines effect the protein-polymer interaction (note G3.5 PAMAM still has 
amine groups within its structure, but not at the surface). Two other studies, both using tertiary 
amine containing dendrimers, showed inhibitory effects of α-synuclein aggregation [239, 240]. As 
mentioned before for amyloid β protein, extrapolation of results to fibrillation inhibition mechanisms 
is difficult. For instance, many other amine containing polymers, including poly-L-lysine and PEI 
have been shown to increase the rate of α-synuclein aggregation [241], showing that a simple 
amine-protein interaction is perhaps not all that is required.  
Many flavonoids have been shown to inhibit the fibrillation of α-synuclein [242] and a mechanistic 
study of the flavonoid-protein interaction elucidates that the oxidized form (quinone containing 
molecule (see figure 21) of the flavonoid plays a major role [243]. To highlight the role that the 
quinone group plays in inhibiting fibrillation, quercetin, a molecule that self oxidizes to the quinone 
form, was added to α-synuclein after different incubation times (and therefore different stages of 
the oxidizing process) [244]. The freshly prepared quercetin exhibited almost no inhibitor effect 
compared to a large inhibitory effect on fibrillization when the oxidized (left for 48 hours) quercetin 
was used. 
---FIGURE 21--- 
This data should therefore suggest that other molecules such as dopamine or L-dopa should have 
intrinsic anti-fibrillation properties in their oxidized form which would contain a quinone group. 
Indeed, studies have shown that not only does dopamine inhibit fibrillization of α-synuclein [245] 
but that amyloid fibrils can be disaggregated by dopamine and L-dopa [246]. Future polymer based 
interventions in protein aggregation may utilize simple chemistries such as the Michael type 
reaction to link several dopamine molecules together, to form hyperbranched structures similar to 
the quinone containing polydopamine used as a tissue adhesive [247].  The high branching 
degree, ability to biodegrade and low toxicity of such materials could be a useful alternative to 
amine containing dendrimers which typically exert cytotoxic effects. Indeed the toxicity of a 
material proposed for inhibiting protein fibrillization, is of utmost importance as a recent study using 
n-acetyl-L-cysteine capped quantum dots to inhibit beta amyloid fibrillation serves to highlight 
[248]. The quantum dots exhibited a dose dependent toxicity which the authors took into account 
whilst analyzing the toxicity of beta amyloid aggregates in the presence or absence of the quantum 
dots in an in vitro system.  Such studies are important, as they place the inhibition qualities of the 
material into context by balancing them with the negative effects of the material. To maximize 
efficiency and minimize off-target effects, the polymers could be designed to incorporate moieties 
with a specific affinity to the disease protein, such as liposomes containing phosphatidic acid to 
bind amyloid-β [249]. Care should be also be paid to the use of heparin based hydrogel materials 
in the brain (see section 4.5) as glycosaminoglycans have also been shown to promote the 
fibrillation of α-synuclein in vitro [250]. Inhibiting the fibrillation of α-synuclein could be of major 
importance for future PD intervention, especially considering the recent finding that fibrillation of 
α-synuclein spreads to anatomically connected areas of the brain [251, 252].  
4.4. Growth Factor Delivery Systems 
The ability of growth factors such as NGF, GDNF and BDNF to protect neurons in animal models 
of neurodegenerative diseases is well documented [8, 9]. They act through differing cell signaling 
pathways (simplified in figure 22) which result in changes in Ca2+ release, neurite outgrowth/axon 
branching, and of particular interest for PD, they exhibit neuroprotection [253, 254].  
---FIGURE 22--- 
In 1993 GDNF was discovered to enhance the survival of midbrain dopaminergic neurons [255], 
and has since been the focus of extensive study as a potential PD therapy. Just three years after 
discovery of the protein, GDNF therapy for PD entered initiation stages for clinical trials. One open 
label phase trial showed positive outcomes [256] not present in the follow up randomized control 
trial [257]. Meanwhile, patients with moderate to advanced sporadic form of PD had been selected 
for infusion of GDNF into intracerebroventricular space (ICV) where no improvements were seen 
and side effects were observed [258]. This was contrary to previous findings in rat and monkey 
PD models, which showed GDNF administered in a similar fashion, exerted neuroprotection and 
functional recovery [6, 259-261]. The inconsistency in results obtained by direct administration of 
the recombinant protein suggests that effective delivery remains the crux of the problem for clinical 
translation [7].  
Research groups have since also focused attention upon biomaterial based strategies to allow 
sustained release of growth factors from materials such as microspheres and hydrogels [11, 12]. 
Whilst catheter design has vastly improved since the early trials [262], polymeric implants that 
sustain the release of growth factors could potentially negate the use of infusion pumps and 
catheters in the future.  
To achieve controlled growth factor release in the brain, one early study embedded a bovine 
serum albumin/NGF mix into molded poly(ethylene-co-vinyl acetate) [263], whilst another showed 
that NGF delivered via PLGA microspheres could prevent excitotoxic damage induced by striatal 
infusion of quinolinic acid [264]. Just as with drug delivery to the CNS (section 4.1), the vast 
majority of growth factor delivery vehicles are comprised of PLGA, however a microparticle 
composed of a PLGA outer layer and collagen inner layer was fabricated in an attempt to reduce 
the burst release typical of PLGA vehicles and most biomaterial delivery systems in general [265]. 
The GDNF delivered was modified to contain a collagen binding peptide, thus allowing it to have 
an affinity to the collagen. However, growth factors typically couple to macromolecules with 
charged domains such as heparin [24, 59, 266] and collagen [267-269], and a study made use of 
this electrostatic interaction to deliver NGF to neurons in vitro via microspheres made of starPEG 
crosslinked collagen [270].    
In terms of microsphere mediated delivery of GDNF to rodent models of Parkinson’s disease, early 
studies showed that impressive behavioral improvements or tyrosine hydroxylase expressing 
neuron retention could be achieved [271-273]. However, the treatment group in these cases was 
compared to either empty microspheres or untreated animals, thus not showing the effect of a 
single injection of GDNF alone. More recent studies have confirmed these findings [274, 275] with 
long term functional benefits being observed for up to 30 weeks [275], showing that PLGA 
mediated delivery of GDNF could be a good future therapy strategy for PD. Interestingly, a PLGA 
microsphere study that delivered vascular endothelial growth factor (VEGF), previously shown to 
have neuroprotective effects on dopaminergic neurons in vitro and in vivo [276], in conjunction 
with GDNF, showed little or no improvement in a combined effect of both growth factors compared 
to the GDNF alone group [277] showing the high potency of GDNF itself. It must be noted here 
that another study, encapsulating both VEGF and GDNF in PLGA nanoparticles did show a 
synergistic effect on nigral neuron survival in the 6-OHDA rat model [278], so this research area 
requires more study for clarification.  
---Table 3--- 
It is clear from the numerous studies that using polymers to encapsulate or bind growth factors 
can lead to functional improvements in animal models of PD. Much progress has been made to 
sustain the release of bioactive neurotrophic factors, a process necessary to overcome the 
problem of short protein half-lives in vivo. There are a host of other growth factors with 
neuroprotective properties which could be analyzed in control delivery systems including neurturin 
[227], insulin like growth factor (IGF-1) [279, 280], conserved dopamine neurotrophic factor [281], 
fibroblast growth factor [282], or mesencephalic astrocyte-derived neurotrophic factor [283] etc. 
One problem associated with biomaterial delivery systems is that they often However, the vast 
majority of the aforementioned studies show a burst release (a rate of release typically much 
higher at the start than later on) of the growth factor of over couple of days. This release pattern 
may arguably be useful for a range of applications; however achieving zero-order release kinetics 
(rate of release is independent of concentration, i.e. steady release) could be really interesting for 
PD research for better delivery of dopamine or sustaining therapeutic neurotrophin levels for 
longer. High aspect ratio tubular structures possibly may afford such release, however potential 
toxicity issues must be considered. Another route could utilize the concept of a “pepper pot” 
whereby the drug is stored in high quantity behind a release limiting pore size [284], however, 
scaling such a device down to the microscale for injectability would be no small feat. Lastly, the 
simple but effective concept of using microfluidic devices to form PLGA with an outer coating of 
alginate allowed near zero-order release of the model drug rifampicin in vitro as shown in figure 
23 [285].  
---FIGURE 23--- 
Obviously drugs and growth factors will have vastly different release profiles, and even bovine 
serum albumin and GDNF have been shown to have differing release kinetics from the same type 
of microsphere (poly (ε-caprolactone)) [286]. However, designing delivery systems to control the 
release of therapeutic molecules is of high importance to PD research. Injectable hydrogels 
present another means of growth factor delivery to the brain either alone [23, 25] or encapsulating 
loaded microparticles [287]. Studies have focused on hydrogel mediated delivery of growth factors 
for applications in stroke [25] and HD [23], but to date much of the work using hydrogels for 
applications in PD has been to assist cell transplantation (covered in the next section).     
4.5. Polymers Designed to Assist Cell Transplantation 
The progressive death of dopaminergic neurons in PD provides researchers the rationale for cell 
transplantation. This could be to directly replace the lost neurons with fetal ventral mesencephalon 
tissue or stem cells engineered to differentiate into genuine ventral mesencephalic-like cells prior 
to transplantation. This strategy aims to repair the damaged neural circuits by implanting cells that 
can integrate into the circuitry and take over the function of the cells lost to the disease process.  
With current technology, the implanted cells have to be placed ectopically into the striatum (their 
target area) as when they are placed in the substantia nigra they can extend processes locally but 
not far enough to reach the striatum. Thus, an additional challenge is to find methods of 
encouraging the processes to grow more extended distances to enable synapses with distant 
targets.  A different cell therapy strategy (although one that could in principle be combined with 
circuit repair) is to implant cells that are able to protect the remaining neurons by expressing 
molecules such as neurotrophic factors.  Some cells, such as mesenchymal stem cells, may 
generate such factors naturally, and other may require genetic engineering (see selected reviews 
on the subject of cell transplantation to the brain [288-291]. One obstacle that hinders the 
widespread application of such therapies is the tendency of large numbers of cells to die 
during/soon after the implantation process.  To allow for this, large numbers of cells have to be 
transplanted, which has been a particular problem for primary ventral mesencephalic grafts, 
meaning that multiple fetal samples are required for each transplant. Furthermore, long-term graft 
survival can be rather unpredictable, so strategies are needed to improve cell survival post 
transplantation [292, 293]. Many different biomaterials have been developed for assisting 
transplantation to the CNS, many of which are for applications in spinal cord injury [294-296], 
however some research has been directly applicable to PD. This section provides an overview 
and discussion about how polymer based strategies have been used in an attempt to overcome 
the second obstacle by trying to improve the survival of cells post transplantation to the brain, with 
particular focus on PD. The first strategy is closely related to the previous sections of this review, 
whereby nano/microparticles are co injected with the graft to deliver therapeutic agents such as 
DNA or neurotrophic factors to assist the survival of the cells post transplantation. The second 
strategy uses injectable materials (typically a hydrogel) either to provide an adherent substrate 
(reducing anoikis) or form a soft material barrier between the transplanted cells and their new 
ectopic environment during the early period post transplantation.   
The concept of co-delivering growth factor microparticles with transplanted cells was studied as 
early as 2001 when Mahoney and Saltzmann pre-cultured cells with NGF releasing PLGA 
microparticles [297]. This system was used as a means of achieving higher choline 
acetyltransferase activity (measure of cholinergic cell function) from the transplanted fetal brain 
cells, and cell survival was not studied.  However, cell survival was measured in a study where 
PLGA microspheres were used to deliver GDNF to the striatum during the grafting of ventral 
mesencephalic tissue either at the site of the injection or a site directly adjacent to it [298]. 
Unloaded or loaded microspheres were used, but little beneficial effects were observed, which the 
authors contributed to the small total amount of GDNF released from the spheres. In addition the 
in vitro release profile showed nearly all of the GDNF being released within the first day. The same 
group then coated the aforementioned PLGA microspheres with poly-D-lysine (PDL) to allow cell 
attachment. These pharmacologically active microcarriers were pre-cultivated with ventral 
mesencephalic cells and the cell/sphere complex was delivered to the 6-OHDA PD rat model 
[299]. Interestingly, delivering the cells whilst attached to the microcarriers, whether loaded with 
GDNF or not, vastly improved their survival (as measured by the number of TH positive neurons). 
This gives the rationale for other studies to be performed with pre-loaded injectable materials, 
such as using PLL coated glass spheres to deliver neurons [47], or the further investigation into 
the use of pharmacologically active microcarriers to deliver MSCs [300]. In the case of MSCs, 
prior loading of microcarriers with the growth factor NT-3 further promoted MSC survival over the 
cell transplant alone group [300].  
---FIGURE 24--- 
Injectable materials, which gel in situ upon injection [160], offer another potential means of 
protecting cells during transplantation to the brain. Many research groups have focused on using 
biomaterials to deliver cells to the ischemic brain or models of traumatic brain injury [25, 301-306], 
however, studies have also been performed in the striatum or PD animal model.  One such study 
investigated a series of hydrogels, and determined that the in vitro survival of embryonic stem cell 
derived neural precursor cells was greatest with the growth factor reduced Matrigel. The in vivo 
study showed a larger graft volume could be obtained in the healthy mouse brain when the 
Matrigel was used to deliver the cells. Interestingly though however, the Matrigel did not reduce 
the number of cells undergoing apoptosis in the early stages post transplantation (it was in fact 
increased), but did increase the number of proliferating cells. Matrigel is a hydrogel composed of 
extracellular matrix proteins from mouse sarcomas, and as such does not have a well-defined 
structure/composition preferred for clinical translation. Other hydrogel systems, based on 
collagen, have been used to deliver cells to the rodent brain [15, 307]. The star shaped PEG 
crosslinker has been used (terminated with succinimidyl glutarate) to crosslink collagen type 1 (via 
the collagen amine groups) during the injection process, thus forming a hydrogel around the cells 
post transplantation (see schematic representation in figure 25) [15].  
---FIGURE 25--- 
Despite a reduction in the microglial invasion/astrocyte scar observed around the graft site when 
the hydrogel was used, no increase in mesenchymal stem cell survival was observed. A study 
which used a collagen hydrogel, functionalized by the spontaneous binding of two laminin derived 
peptides, showed an increase in the survival of neural stem cells post transplantation [307]. It 
should be noted however, that the non-functionalized collagen hydrogel achieved no such 
increase in cell survival (which is in accordance with the aforementioned starPEG/collagen 
hydrogel), so the laminin derived peptides must be playing an important role in survival.  
---Table 4--- 
Polymer based hydrogels hold the potential to provide useful assistance for cell transplantation 
therapies for diseases such as PD. They can reduce the shear stress that cells undergo during 
injection [312], however, typical flow rates for injection into the brain are very low (1 µl/min) [15, 
16]. In addition hydrogels have been shown to reduce the host response at the site of 
transplantation [15], and they can provide a barrier to the ectopic environment. Whilst the adherent 
properties of the hydrogel are clearly very important [307], and potentially could be manipulated 
by the inclusion of dopamine itself [313, 314], there is also a growing rationale for preloading cells 
to an injectable substrate to mediate improved survival [47, 299, 300]. The development of 
hydrogel technology and micro contact printing have allowed pre-formed, cell seeded hydrogels 
of varying sizes to be easily produced [315], which could be adapted for applications in PD. 
Perhaps the ideas of injectable hydrogels and pre-adhered cells could be combined in a shear-
thinning hydrogel whereby cells at the center of the hydrogel experience very little shear force 
[159] and remain adhered to the hydrogel throughout the injection process [158]. Then it becomes 
easy to envisage further modification of the shear thinning hydrogel to incorporate trophic support 
for neurons [316], or other anti PD drugs in general. Polymer constructs may contribute to 
improving cell transplantation for PD in other, less foreseeable ways, such as assisting the during 
the cell growth stage prior to injection. For example the manipulation of stem cells prior to injection 
[317], or encouraging  sphere growth via thermoresponsive patterned culture substrates [318].  
5. A Note on Clinical Translation and Clinical Trials 
This review has paid particular attention to the potential application of polymer-based therapeutics 
for PD. To date, research in this field has been largely carried out either in vitro, or via the use of 
in vivo models of the disease, with little application in the clinic. Here the authors briefly consider 
where clinical translation is likely to occur for PD and other neurodegenerative conditions for the 
aforementioned polymer-based strategies (drug/gene/growth factor/cell delivery).  
It is likely that an early translational target will be controlling drug concentrations within the blood 
stream over extended periods. Currently, coating the active ingredient provides a means of 
prolonging the delivery of PD drugs ropinirole (clinical trials.gov identifier = NCT00331149, 
reviewed [319]) and amantadine HCl (clinical trials.gov identifier = NCT02153632). In addition, gel 
based delivery of drugs may allow sustained delivery, such as interintestinal delivery of 
DUODOPA® (levoDopa/carbidopa clinical trials.gov identifier = NCT01754129, [320]). To date, 
gene therapy trials for neurodegenerative diseases have all used a viral vector for the delivery of 
the genetic information, for example, CERE-120 – Neurturin for PD (clinical trials.gov identifier = 
NCT00985517, [227] reviewed, [321]), CERE-110 – NGF for AD (clinical trials.gov identifier = 
NCT00876863, [225] reviewed, [322]) or ProSavin (clinical trials.gov identifier = NCT00627588, 
[228]). Originally the safety concern associated with the use of viral vectors was a major driving 
force for non-viral gene vector development; however, as these trials increasingly show safety and 
tolerability of the vector, it is likely that non-viral vectors will be desired for other reasons. The 
simplicity and scalability of some methods of polymeric vector manufacture, particularly “one-pot” 
reactions that keep intrinsic functionality for specific modification [323], could allow a more broad 
scale translation of the therapy to the vast number of patients with neurodegenerative disorders. 
Perhaps viral vectors will pave the way, showing proof-of-concept for gene therapy in the human 
brain and, if efficiency can be improved, lead to a polymer-based therapy on a larger scale. 
Currently several polymer gene vector clinical trials are underway (reviewed in full elsewhere, 
[324]) with the majority focusing on anti-cancer activity, with one analyzing the use of a lipid vector 
for glioma therapy (clinical trials.gov identifier = NCT00734682). 
One polymer assisted therapeutic strategy for neurodegenerative disorders which is well 
underway in clinical investigation is ex vivo gene therapy: an overlap between cell therapy and 
growth factor delivery to the brain. A variety of polymers such as polyethersulfone, 
poly(acrylonitrile vinyl chloride) and poly-l-lysine to name but a few (see review for full list [325]) 
have been used to create matrix materials as a hollow fibers/microcapsules that encapsulates 
cells, usually on a supportive matrix (see Figure 26) [326].  
---FIGURE 26--- 
This encapsulation technology effectively shields transplanted cells from the host immune system, 
and so can be referred to as immunoisolated cell transplants. Cells that secrete neuroprotective 
proteins can be encapsulated in these devices so that immune cells cannot enter, but the desired 
protein can reach the surrounding tissue. With over twenty years since the early studies of 
encapsulation technology [327], this field of study has entered clinical trials with some promising 
results and the reader is referred to the following reviews on the subject [42, 328]. This technology 
has the potential for applications in a range of neurodegenerative disorders such as HD [329], AD 
[41], and PD (ongoing, clinical trials.gov identifier = NCT01734733). Unlike gene therapy, the 
protein production can be halted by device retraction. This approach is also limited to ex vivo 
delivery of proteins from the transplanted cells, and of course does not include cell therapies which 
require the cells to integrate with the host as cell replacement therapies intend. As stated in section 
4.5, anoikis may play a significant role in cell death post transplantation [330], and so gelatin 
microcarriers have also entered the clinic as an injectable cell culture platform for a trial involving 
the transplantation of retinal epithelial cells for PD [331]. The small quantity, but highly promising 
data on microcarrier based transplantation, suggests that the development of simple cell adherent 
platforms have the potential to impact on future cell transplantation strategies.      
6. Conclusions 
This review has focused on five key areas of neuroscience research where polymer materials may 
affect future therapies for neurodegenerative diseases such as PD: drug delivery, gene delivery, 
protein fibrillation, growth factor delivery and cell transplantation. We find ourselves in a situation 
where delivery is a critical issue to be resolved, especially in the cases where the key 
drug/cell/molecule is known but present delivery methods render the effects transient, variable, 
inefficacious or exacerbates side effects. In summary polymer therapeutics may: 1) assist drug 
delivery to the brain and control release, 2) provide a cheaper/more scalable alternative to viral 
gene vectors, 3) offer an interesting means of studying protein fibrillation, 4) allow sustained 
growth factor release, and finally 5) allow better survival of cells that are transplanted to the brain. 
Presently, the use of polymers in these areas lags behind their non-polymeric counterpart (e.g. 
oral L-DOPA therapy, adenoviral gene delivery, or fetal cell transplantation), but shows interesting 
early signs of the improvements that could be made if such technology is embraced and developed 
further. Although clinical translation is not yet a reality for most of the technologies covered in this 
review, and some, such as anti-fibrillation polymers for understanding the aggregation and 
cytotoxicity of aggregated proteins, may remain as powerful research tools, others, such as 
microcarriers designed to improve cell implantation in the brain, may become a clinical reality in 
the not too distant future due to the conceptual simplicity and range of regulatory approved cell 
adherent polymers.    
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Delivery System Drug/ 
Administration 
Method 
Animal/ 
Model 
Summary Year/ 
Reference 
Chitosan 
nanoparticles 
Dopamine  
intraperitoneal 
Healthy rat Acute administration of dopamine 
loaded nanoparticles induced a dose-
dependent rise in striatal DA output 
(2011) 
 [178] 
PLGA 
microspheres 
Levodopa methyl 
ester and 
benserazide  
subcutaneous  
6-OHDA rat Loaded microspheres improved 
stepping of the lesioned forepaw and 
decreased apomorphine-induced 
turns  
(2011) 
 [183] 
PLGA 
microspheres 
L-dopa-α-lipoic acid 
(LD-LA)  
subcutaneous 
Healthy rat Microsphere delivery provided 
sustained levels of striatal dopamine 
for up to 4 days after a single 
administration 
(2011)  
[184] 
PLGA 
microspheres 
Levodopa methyl 
ester and 
benserazide  
subcutaneous 
6-OHDA rats 
with 
levodopa 
induced 
dyskinesias 
Levodopa/benserazide delivered by  
microspheres resulted in lower 
abnormal involuntary movement (AIM) 
scores than the administration of the 
free drug 
(2011) 
[185] 
Odorranalectin-
conjugated PEG-
PLGA nanoparticles 
Urocortin peptide  
intranasal  
6-OHDA rat Odorranalectin modification of the 
nanoparticles increased brain uptake 
and therapeutic effect of the Urocortin 
peptide 
(2011) 
[104] 
Lactoferrin 
conjugated PEG-
PLGA nanoparticles 
Urocortin peptide  
intravenous 
6-OHDA rat Urocortin loaded nanoparticles 
improved behavioral function and 
striatal innervation 
(2011) 
[194] 
PLGA 
microspheres 
Rotigotine  
intramuscular  
6-OHDA rat 
–subgroup 
with 
dyskinesias 
The combination of microsphere and 
pulsatile L-DOPA delivery produced 
no better therapeutic benefit than 
mono L-DOPA administration but 
significantly decreased dyskinesia 
(2012) 
[195] 
PLGA 
microspheres 
Rasagiline mesylate 
(RM) intraperitoneal 
Rotenone rat 
model 
RM administered via microspheres 
resulted in no additional therapeutic 
than RM in saline, but allowed 
administration every two weeks 
(2012) 
[196] 
PLGA 
microspheres 
Rotigotine  
intramuscular 
Cynomolgus 
monkey 
The safety profile of Rotigotine loaded 
microspheres was analyzed and 
deemed safe prior to clinical trials 
(2013) 
[197] 
Table 1 - Recent progress in polymer assisted drug delivery for PD 
 
 
 
 
 
 
Gene 
Vector 
Material 
Functional-
ization 
Gene 
Delivered/ 
Administration 
Method 
Animal 
Model 
Summary Year/ 
Reference 
PLL Neurotensin GDNF  
intrastriatal 
6-OHDA 
rat 
Transfection in the substantia 
nigra 1 week after 6-OHDA 
produced biochemical, 
anatomical, and functional 
recovery 
(2006) 
[208] 
PEG 
substituted 
lysine 30-
mer 
peptides 
- GDNF  
intrastriatal 
Healthy 
rat 
Striatal transgene expression 
lasted up to 8 weeks, at levels at 
least 100-fold greater than 
intracerebral injections of naked 
DNA plasmids 
(2009) 
[209] 
PAMAM Lactoferrin GDNF   
intravenous 
6-OHDA 
rat 
Multiple injections improved 
locomotor activity and reduced 
dopaminergic neuronal loss 
(2009) 
[119] 
PAMAM Lactoferrin GDNF   
intravenous 
Rotenone 
rat model 
Above mentioned effects also 
observed in the rotenone PD 
model 
(2010) 
[217] 
PEG 
substituted 
lysine 30-
mer 
peptides 
- GDNF  
intrastriatal 
Healthy 
rat and 6-
OHDA rat 
GDNF transgene activity 
observed up to 6 months after a 
single administration 
(2011) 
[210] 
PEG - PLL Angiopep GDNF  
intravenous 
Rotenone 
rat model 
Improved locomotor activity and 
recovery of dopaminergic 
neurons 
(2013) 
[214] 
PEG - PLL Rabies virus 
glycoprotein 
peptide 
Anti caspase 3 
RNAi 
intravenous 
Rotenone 
rat model 
Weekly administration reduced 
activated casapse-3 levels and 
improved locomotor activity and 
rescued dopaminergic neuronal 
loss  
(2013) 
[118] 
Table 2 - Significant studies using a therapeutic nucleic acid delivered to the rodent brain 
 
 
 
 
 
 
 
 
 
 
Delivery System Growth Factor/ 
Administration 
Method 
Model/ Animal  Summary Year/ 
Reference 
PLGA 
microspheres 
GDNF - 
intrastriatal 
6-OHDA rat Motor behavior restoration and higher 
fiber density in the GDNF treated 
striatum 
(2009) 
[274] 
PLGA 
microspheres 
GDNF - 
intrastriatal 
6-OHDA rat Complete behavioral recovery 
(amphetamine induced rotation test) 
after 16 weeks of treatment 
(2011) 
[275] 
Polybutylcyanoacryl
ate nanoparticles 
coated with 
polysorbate-80 
NGF - 
intraperitoneal 
MPTP mouse Decreased rigidity and increased 
locomotor activity compared to control 
mice receiving MPTP alone 
(2008) 
[279] 
Polybutylcyanoacryl
ate nanoparticles 
coated with 
polysorbate-80 
NGF - 
intraperitoneal 
MPTP mouse Polysorbate-80 required for brain 
uptake. Maximum NGF concentration 
detected 45 mins post administraiton 
(2009) 
[280] 
PLGA 
microspheres 
VEGF and 
GDNF - 
intrastriatal 
6-OHDA rat GDNF microspheres more successful 
in bringing functional recovery than 
VEGF microspheres. Little or no 
combined effect, suggesting GDNF is 
dominant. 
(2013) 
[277] 
PLGA nanospheres VEGF and 
GDNF - 
intrastriatal 
6-OHDA rat Combined effect of VEGF and GDNF 
in neuron density in the striatum 
(2014)  
[278] 
Table 3 - Recent studies delivering growth factors to the Parkinsonian rodent brain 
 
 
  
 
 
 
 
 
 
 
 
Cell Type 
Delivered 
Material Growth 
Factor 
Animal 
Model 
Summary Year/ 
References 
Ventral 
mesencephalic 
tissue/suspension 
Polyethylene 
glycol (PEG)-
substituted 
lysine 30-mers 
Gene 
encoding 
GDNF 
6-OHDA 
rat 
Pretransfected tissue showed a 
16-fold increase in surviving 
neurons, and the pretransfected 
striatum allowed a seven-fold 
increase in survival compared to 
saline treated controls.  
(2009) 
[308] 
Embryonic Stem 
Cell-Derived 
Neural Precursor 
Cells 
Growth factor-
reduced 
Matrigel (and 
others) 
- Healthy 
adult 
mouse 
Matrigel promoted proliferation 
of grafted cells resulting in a 
larger graft volume and more 
dopaminergic neurons in the 
graft. 
(2010) 
[309] 
Multipotent 
mesenchymal 
stromal cells 
PLL coated 
PLGA 
microspheres 
NT3 6-OHDA 
rat 
Microsphere cell delivery 
reduced amphetamine-induced 
rotational behavior and allowed 
protection/repair of the 
nigrostriatal pathway 
(2011) 
[300] 
Neural stem cells Poly ε-
caprolactone 
scaffolds 
GDNF Healthy 
rat 
GDNF loaded scaffolds 
enhanced transplant survival, 
proliferation, migration, and 
neurite growth and suppressed 
inflammatory reactive astroglia. 
(2012) 
[310] 
Neural stem cells Laminin-derived 
IKVAV motif 
functionalized 
self-assembling 
peptide RADA16 
- Healthy 
adult rat 
with 
cortex 
biopsy 
The hydrogel formed 
immediately in situ enhancing 
cell survival and reducing the 
surrounding of glial astrocytes 
(2013) 
[311] 
GDNF secreting 
mesenchymal 
stem cells 
Star PEG 
crosslinked 
collagen 
hydrogel 
Secreted 
GDNF 
Healthy 
adult rat 
and 6-
OHDA 
rat 
The collagen hydrogel reduced 
the host response to the cells by 
reducing the recruitment of  
microglia and astrocytes to the 
graft site 
(2013) 
[15] 
Table 4 - Cell transplantation studies using various biomaterial platforms with the aim of improving cell 
survival post transplantation to the brain. 
 
 
 
 
 
 
Figure 1 - Representation of how polymers may play a role in Parkinson's disease research 
 
Neural stem cells Collagen 
hydrogel 
functionalized 
with laminin 
derived peptide 
(collagen-
binding LG3 
(CLG3) and 
histidine-tagged 
LP (HLP)) 
- Healthy 
adult rat 
The collagen hydrogel improved  
neural stem cells viability in the 
early stage after transplantation 
into the striatum 
(2013) 
[307] 
 Figure 2 - Schematic representations of the human brain (left) with a zoomed cross-section (right), showing 
the nigrostriatal pathway (depicted in green) affected in Parkinson's disease. The dopaminergic neuron cell 
bodies lie in the substantia nigra and project into the striatum. 
 
 
 
Figure 3 - DRG cell outgrowth within MMP cleavable PEGylated fibrinogen hydrogel. The left hand image 
shows the control (without MMP) allowing neurite outgrowth through the hydrogel, showing that the cell can 
manipulate its surrounding. However, MMP-2/9 inhibitor decreased the neuronal but not the nonneuronal 
outgrowth at the C/3 and C/2 concentrations and obstructed completely any outgrowth at the C 
concentration (day 2 of experiment); scale bar = 500µm. Image taken with permission from reference [61] 
and adapted to show one experimental group.   
 
 Figure 4 - Schematic diagram showing the route to in situ forming hydrogels formed from starPEG and 
heparin via Michael type addition. Cell adhesion peptides (green) can be added to mono-substitute the PEG 
via the maleimide group, while the remaining arms are substituted with a bifunctional MMP cleavable peptide 
sequence (blue) allowing gelation with maleimide modified heparin. Note that growth factors can also be 
added during the last step to functionalize the hydrogel. Reprinted with permission from [59]. 
 
 Figure 5 - A library of monomers (a) can be used to make acid-degradable polymers. Part (b) shows the 
acid cleavable monomer 10, and the activation of monomers. Part (c) shows the polymerization of activated 
monomers with the acid-cleavable monomer, to form fully degradable polymers (via mechanism shown in 
(e)) capable of protein delivery to cells etc (d). Reproduced with permission from [65]. Copyright (2008) 
American Chemical Society. 
 Figure 6 - Synthetic route to biodegradable branched PEI functionalized with the rabies virus glycoprotein 
for nucleic acid delivery to the brain. Reproduced with permission from [72]. 
 Figure 7 - Schematic depiction and gel permeation chromatography data of a disulfide linked knot structured 
polymer. Notice how cleavage of the disulfide bond does not affect the carbon-carbon bonded backbone, 
so no reduction in molecular weight is observed, only an increase due to increased hydrodynamic volume. 
Reproduced from [78] by permission of The Royal Society of Chemistry. 
 
Figure 8 - Schematic representation of the complexities capable for molecule delivery via polymer 
therapeutics. Reproduced with permission from Proceedings of the National Academy of Sciences of the 
United States of America (ref. [99]; copyright 2010, National Academy of Sciences, USA). 
 Figure 9 - Mechanism of reversible termination during controlled living radical polymerization, as shown in 
[135].  
 
Figure 10 - Schematic depiction of the major polymer structures available for biomaterial synthesis, ranging 
from small molecules to macroscale crosslinked networks for hydrogel preparation. 
 
 
 
 
 
 
 
 
 Figure 11 - Examples of vinyl monomers used for radical polymerization (type denoted in brackets), of 
nucleic acid vectors, taken directly from [68] with permission. 
 
 Figure 12 - The preparation of star and star block copolymers by the in situ generated core method, image 
Reprinted with permission from [149]. Copyright (2008) American Chemical Society. 
 
Figure 13 - Atom transfer radical polymerization is a versatile means to allow internal cyclization 
(intramolecular crosslinks) within the polymer structures developed for gene delivery, reproduced from [78] 
by permission of The Royal Society of Chemistry. 
 Figure 14 - Schematic representation of a glutathione sensitive polymer that undergoes crosslinking after 
the addition of cellular concentrations of glutathione. The disulphide bonds are cleaved, forming thiol groups 
which crosslink the polymer chains via free vinyl groups throughout the polymer structure. Reproduced from 
[157] by permission of The Royal Society of Chemistry. 
 
Figure 15 - Chemical structure of PLGA and its subsequent break down products 
 
Figure 16 - A graph showing how delivery of L-DOPA via PLGA microspheres allow sustained levels of 
dopamine in the rat striatum. L-DOPA administered subcutaneously (LD s.c.) or orally (LD os) gave short 
lived dopamine levels. L-dopa-a-lipoic acid (LD-LA s.c.) gave better duration of dopamine, but when loaded 
to microspheres (LD-LAMs s.c.) striatal dopamine was elevated for over four days. Graph reproduced with 
permission from [184]. Copyright (2011) American Chemical Society. 
 
 Figure 17 - Neurotensin modified polyplexes for the delivery of the GDNF encoding gene . The upper panel 
shows the site of the lesion and vector injection. The lower part shows the re-innervation of the substantia 
nigra (SNc) (left) and striatum (middle/right) following GDNF gene therapy. Figures reproduced with 
permission from [207]. 
 Figure 18 - Image taken with permission from [73], to highlight that although achieving high transfection 
capability in the brain is an important goal, off-target gene expression is a serious hurdle to overcome. Blue 
areas represent tissue of high transgene activity, and non-targeted gene administration (left hand side) 
shows no transgene activity in the brain. RVG targeted delivery shows transgene activity in the brain, but 
also large off-target delivery, especially in the kidney and liver.  
 
Figure 19 - Showing possible fibrillation mechanisms of amyloid β (monomers shown as open circles, 
oligomers as yellow squares), and the interaction with polymer nanoparticles (grey). Reprinted with 
permission from [234]. Copyright (2008) American Chemical Society. 
 Figure 20 - Inhibition of the fibrillation of amyloid β depends on the concentration of the polmer nanoparticles. 
Low concentrations (green data) speed up the fibrillation process, whereas high concentrations stopped 
fibril formation. Reprinted with permission from [236]. Copyright (2010) American Chemical Society. 
 
Figure 21 - Chemical structures of molecules used to inhibit α-synuclein aggregation in vitro, including the 
flavanoids baicalein, quercetin (and its oxidized form - quercetinchinone).  
 
 
 
 
 Figure 22 – The action of trophic factors on cell surface receptor complexes. The action of GDNF, neurturin 
(NTN) and neurotrphin-3 (NT-3) may act on more than one receptor (dashed arrow) though the major 
interaction is indicated by the solid arrow. The cellular signalling pathways activated cause a variety of 
outcomes including Ca2+ release, neurite outgrowth and neuron branching, but for PD only the effect of 
neuroprotection is indicated (inspiration taken from reference [253]). N.B. BDNF = brain derived 
neurotrophic factor, ATN = artenin, PSP =persephin. 
 
Figure 23 - Drug release (rifampicin) from microspheres of varying diameter, featured here to show the near 
zero-order release of drug possible from PLGA based microspheres. The left hand panel shows no more 
than 5% of the drug is released after the first day, and the right panel shows the length of time release is 
achieved. Selected from [285], with reprint permission.  
 Figure 24 - Light microscope image (A) and scanning electron microscope image (B) showing fetal ventral 
mesencephalic cells growing on pharmacologically active microcarriers with neurite projections. Images 
used with permission from [301]. 
 
Figure 25 - Schematic presentation of the process of forming cell loaded, in situ forming hydrogels in 
preparation for in vitro or in vivo analysis. Reproduced with permission from [15]. 
 
 Figure 26 – Representation of a polymer device encapsulating cells for the delivery of therapeutics to the 
brain. It must be implanted by sterotactic surgery but has the advantage of device removal if required. 
Reproduced with permission from [326]. 
 
 
